BEVERLY, MA–(Marketwired – August 11, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, would like to provide additional information regarding the Company’s Phase 1 trial of Kevetrin in patients with advanced solid tumors who have no other treatment options. Cellceutix has received many inquiries for more information related to the disclosure in a press release on Friday, August 7, 2015 of a patient in the trial entering the eleventh month of therapy, as the cancer type was not disclosed.
The patient, now in his eleventh month of treatment, is being treated with Kevetrin for Stage 4 thymoma, a rare disease in which cancer cells form on the outside surface of the thymus. The patient’s disease is considered stabilized, as information to date shows a slight reduction (approximately 6 percent) in tumor size. The patient reports feeling better than before and side effects have been minimal.
Cellceutix is encouraged by the information received to date. The Company will be analyzing all the data from the trial to determine which indications will be considered for an Orphan Drug application with the U.S. Food and Drug Administration and advanced clinical trials.